axitinib after sunitinib in metastatic renal cancer: preliminary results from italian “real-word” sax study
Clicks: 256
ID: 132966
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
256 views
54 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #225 of 333 articles by views in chemical research in chinese universities
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in second-line treatment of mRCC. The medical records of 62 patients treated with Axitinib, were retrospectively reviewed. The Progression Free Survival (PFS), the Overall Survival (OS), the Objective Response Rate (ORR), the Disease Control Rate (DCR) and the safety profile of axitinib and sunitinib-axitinib sequence, were the primary endpoint. The mPFS was 5.83 months (95% CI 3.93-7.73 months). When patients was stratified by Heng score, mPFS was 5.73, 5.83, 10.03 months according to poor, intermediate and favourable risk group respectively. The mOS from the start of axitinib was 13.3 months (95% CI 8.6-17.9 months); the observed ORR and DCR were 25% and 71%, respectively. When stratified patients by subgroups defined by duration of prior therapy with Sunitinib (≤ vs >median duration), there was a statistically significant difference in mPFS with 8.9 ( 95% CI 4.39-13.40 months) vs 5.46 months (95% CI 4.04-6.88 months) for patients with a median duration of Sunitinib >13.2 months. DCR and ORR to previous Sunitinib treatment was associated with longer statistically mPFS, 7.23 (95% CI 3.95-10.51 mo, p=0.01) and 8.67 (95% CI 4.0-13.33 mo, p=0.008) vs 2.97 (95% CI 0.65-5.27 mo, p=0.01) and 2.97 months (95% CI 0.66-5.28 mo, p=0.01) respectively. Overall Axitinib at standard schedule of 5 mg bid, was well tolerated. The most common adverse events of all grades were fatigue (25.6%), hypertension (22.6%), gastro-intestinal disorders (25.9%) and hypothyroidism (16.1%). The sequence Sunitinib-Axitinib was well tollerated without worsening in side effects, with a median OS of 34.7 months (95% CI 18.4-51.0 months). Our results are consistent with the available literature; this retrospective analysis confirms that Axitinib is effective and safe in routine clinical practice.
| Reference Key |
d'aniello2016frontiersaxitinib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Carmine D'Aniello;Maria Giuseppa Vitale;Azzurra Farnese;Lorenzo Calvetti;Maria Maddalena Laterza;Carla Cavaliere;Chiara Della Pepa;Vincenza Conteduca;Anna Crispo;Ferdinando De Vita;Francesco Grillone;Enrico Ricevuto;Michele De Tursi;Rocco De Vivo;Marilena Di Napoli;Sabrina Chiara Cecere;Gelsomina Iovane;Alfonso Amore;Raffaele Piscitelli;Giuseppe Quarto;Salvatore Pisconti;Gennaro Ciliberto;Piera Maiolino;Paolo Muto;Sisto Perdona;Massimiliano Berretta;Luca Galli;Giacomo Cartenì;Ugo De Giorgi;Sandro Pignata;GAETANO FACCHINI;Sabrina Rossetti |
| Journal | chemical research in chinese universities |
| Year | 2016 |
| DOI |
10.3389/fphar.2016.00331
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.